VYNDAMAX

This brand name is authorized in Hong Kong, Israel, United States

Active ingredients

The drug VYNDAMAX contains one active pharmaceutical ingredient (API):

1 Tafamidis UNII 8FG9H9D31J - TAFAMIDIS

Tafamidis is a selective stabiliser of transthyretin (TTR). Tafamidis binds to TTR at the thyroxine binding sites, stabilising the tetramer and slowing dissociation into monomers, the rate-limiting step in the pathogenesis of transthyretin amyloidosis. Read about Tafamidis

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
VYNDAMAX Capsule	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N07XX08	Tafamidis	N Nervous system → N07 Other nervous system drugs → N07X Other nervous system drugs → N07XX Other nervous system drugs
Discover more medicines within N07XX08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: HK	Department of Health Drug Office	Identifier(s): 66860
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8550
Country: US	FDA, National Drug Code	Identifier(s): 0069-8730